Response to infliximab in SAPHO syndrome

BMJ Case Reports

Volumn , Issue , 2009, Pages

  Fruehauf, Julia ^a   Cierny Modrè, Brigitte ^a   El Shabrawi Caelen, Laila ^a   Schwarz, Thomas ^a   Weinke, Roland ^a   Aberer, Elisabeth ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869123107     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.10.2008.1145     Document Type: Article

References (16)

1. Earwaker JW, Cotten A. SAPHO: syndrome or concept? Imaging findings. Skeletal Radiol 2003; 32: 311-27. (Pubitemid 36790236)
2. Poindexter G, Martinez S, Roubey RA, et al. Sy nov itis-acne-pustulosis- hyperostosis-osteitis syndrome: A dermatologist's diagnostic dilemma. J Am Acad Dermatol 2008; 59(suppl 1): 53-4.
3. Schilling F, Märker-Hermann E. Chronic recurrent multifocal osteomy elitis in association with chronic inf lammatory bowel disease: entheropathic CRMO. Z Rheumatol 2003; 62: 527-38. (Pubitemid 38121889)
4. Moll C, Hernndez VM, Ca?ete JD, et al. Ilium osteitis as the main manif estation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum 2008; 37: 299-306. (Pubitemid 351389483)
5. Asmussen KH. Successf ul treatment of SAPHO syndrome with infliximab. A case report [abstract]. Arthritis Rheum 2003; 48(suppl): 621.
6. Amital H, Applbaum YH, Aamar S, et al. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology 2004; 43: 658-61. (Pubitemid 38628200)
7. Widmer M, Weishaupt D, et al. Inf liximab in the treatment of SAPHO syndrome: clinical experience and MRI response [abstract]. Ann Rheum Dis 2003; 62(suppl 1): 250-1.
8. Deutschmann A, Mache CJ, Bodo K, et al. Successf ul treatment of chronic recurrent multifocal osteomy elitis with tumor necrosis factor-? blockage. Pediatrics 2005; 116: 1231-3. (Pubitemid 46056433)
9. Massara A, Cav azzini PL, Trotta F. In SAPHO syndrome anti-TNF-? therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manif estations. Rheumatology 2006; 45: 730-3. (Pubitemid 43985342)
10. Alexis AF, Strober BE. Of f-label dermatologic uses of anti-TNF-? therapies. J Cutan Med Surg 2005; 9: 296-302. (Pubitemid 44491079)
11. Freeman HJ. Complications of collagenous colitis. World J Gastroenterol 2008; 14: 1643-5. (Pubitemid 351493368)
12. Schulzke JD, Bojarski C, Zeissig S, et al. Disrupted barrier function through epithelial cell apoptosis. Ann N Y Acad Sci 2006; 1072: 288-99. (Pubitemid 44448461)
13. Iqbal M, Kolodney MS. Acne fulminans with sy nov itis-acne-pustulosis- hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 2005; 52(suppl 1): 118-20.
14. Oliv ieri I, Padula A, Ciancio G, et al. Successf ul treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 61: 375-6. (Pubitemid 34257756)
15. Lutt JR, Deodhar A. Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 2008; 68: 591-606. (Pubitemid 351451539)
16. Flendrie M, Creemers MC, van Riel PL. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) 2007; 46: 146-9. (Pubitemid 44932803)